ciglitazone has been researched along with Pulmonary Disease, Chronic Obstructive in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, HJ | 1 |
| Belvisi, MG | 1 |
| Bishop-Bailey, D | 1 |
| Yacoub, MH | 1 |
| Mitchell, JA | 1 |
1 other study available for ciglitazone and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Apoptosis; Blotting, Western; Cell Division; Cells, Cul | 2003 |